poisar

Stocks · News reference

Camurus Doses First Patient in Mid-stage Trial of Weight-loss Drug CAM2056

Fiscal.ai

Camurus has initiated a Phase 2b clinical trial for its weight-loss drug candidate, CAM2056, by dosing the first patient.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Jefferies Raises Price Target for Camurus

    Investment bank Jefferies has increased its price target for Camurus, citing expectations for accelerated growth of the product Brixadi in the coming year.